Patients Undergoing Microvascular Surgery
Conditions
Keywords
Bemiparine, Antithrombotic microsurgery protocol, Comparative study, Anticoagulant microsurgery protocol
Brief summary
A comparative study to reveal if the use of Bemiparine (Hibor) versus Enoxaparin (Clexane) as an antithrombotic agent, shows an advantage on the rate of thrombotic and haemorrhagic events in microsurgicals free flaps during head and neck reconstruction.
Detailed description
This is an observational post-authorization study on a group of patients undergoing microsurgery on the Oral and Maxillofacial Surgery and Plastic and Reconstructive Surgery Service at Ramon y Cajal Hospital, Madrid for processes that require reconstruction with a flap microvascular. A group of 67 patients treated according protocol postoperative prevention of deep vein thrombosis with Bemiparina will be compared with data collected retrospectively from a group of 134 patients treated previously with an earlier protocol with enoxaparin as main antithrombotic agent.
Interventions
DRUGBemiparine
Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
Sponsors
Rovi Pharmaceuticals Laboratories
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients that will undergo reconstructive surgery for defects in any part of the body, especially in head and neck, after cancer, traumatic or infectious pathology, which will require the use of techniques of microsurgery. * Patients who have given their informed consent * Patients in which it has been decided to use thromboprophylaxis with bemiparina before proposing them to participate in the study.
Exclusion criteria
* Patients not eligible for repair through the use of free flaps, and therefore the use of Microsurgical techniques for vascular anastomosis * Patients with an underlying pathology that may interfere to a clinically significant or contraindicated the use of Bemiparina, such as: serious hepatic or renal insufficiency, uncontrolled arterial hypertension, history of gastroduodenal, thrombocytopenia, nephrolithiasis or uretrolitiasis and vascular disease ulcer of choroid and retina. * Refusal of the patient or their family members to participate in the study. * Pregnancy and breastfeeding * Known hypersensitivity to study drugs or any of its components
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the use of Bemiparine, against Clexane as an antithrombotic agent | 24 months | Incidence thrombotic complications and bleeding |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of deep vein thrombosis and pulmonary embolism | 24 months |
| Incidence of postsurgery hemorrhagic strokes with both drugs | 24 months |
Countries
Spain
Outcome results
None listed